Education
About Us
Working with TipRanks
Follow Us
XORTX Therapeutics Inc (XRTX)
NASDAQ:XRTX
XRTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.80 - $2.98
Previous CloseN/A
Volume19.17K
Average Volume (3M)30.37K
Market Cap
C$3.56M
Enterprise Value$1.36M
Total Cash (Recent Filing)C$2.30M
Total Debt (Recent Filing)C$61.47K
Price to Earnings (P/E)―
Beta0.31
Next Earnings
Aug 13, 2025EPS EstimateN/A
Last Dividend Ex-Date
Jan 31, 2014Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding3,788,246
10 Day Avg. Volume18,949
30 Day Avg. Volume30,373
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.93
Price to Sales (P/S)0.00
P/FCF Ratio-0.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$13.88Price Target Upside1361.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
XORTX Therapeutics Inc News
PremiumCompany Announcements
XORTX Therapeutics Announces $3 Million Offering to Advance Gout Programs
PremiumCompany Announcements
XORTX Therapeutics Reports Q1 2025 Financial ResultsPremiumCompany Announcements
XORTX Therapeutics Delays Yearly Report Filing
PremiumCompany Announcements
XORTX Advances NDA Filing for Gout Treatment Following FDA Guidance
PremiumCompany Announcements
XORTX Secures European Patent for Gout and Kidney Disease TherapiesOptions Prices
Currently, No data available
---
Ownership Overview
XRTX FAQ
What was XORTX Therapeutics Inc’s price range in the past 12 months?
XORTX Therapeutics Inc lowest stock price was $0.80 and its highest was $2.98 in the past 12 months.
What is XORTX Therapeutics Inc’s market cap?
XORTX Therapeutics Inc’s market cap is C$3.56M.
When is XORTX Therapeutics Inc’s upcoming earnings report date?
XORTX Therapeutics Inc’s upcoming earnings report date is Aug 13, 2025 which is in 45 days.
How were XORTX Therapeutics Inc’s earnings last quarter?
XORTX Therapeutics Inc released its earnings results on May 16, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.19.
Is XORTX Therapeutics Inc overvalued?
According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Undervalued.
Does XORTX Therapeutics Inc pay dividends?
XORTX Therapeutics Inc pays a Quarterly dividend of $0.075 which represents an annual dividend yield of N/A. See more information on XORTX Therapeutics Inc dividends here
What is XORTX Therapeutics Inc’s EPS estimate?
XORTX Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XORTX Therapeutics Inc have?
XORTX Therapeutics Inc has 3,788,246 shares outstanding.
What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?
XORTX Therapeutics Inc reported an EPS of -$0.19 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 13.83%.
Which hedge fund is a major shareholder of XORTX Therapeutics Inc?
Currently, no hedge funds are holding shares in XRTX
Company Description
XORTX Therapeutics Inc
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Technical Analysis
Quest Pharmatech
―
Algernon Pharmaceuticals
―
Appili Therapeutics Inc Class A
―
Rakovina Therapeutics Inc
―
Marvel Biosciences Corp
―